{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:46:25Z","timestamp":1793018785799,"version":"4.5.0"},"reference-count":158,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pneumonia"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Respiratory syncytial virus (RSV) causes substantial morbidity and mortality across the lifespan, with the highest burden seen in infants and older adults. Recently approved immunizing agents, including long-acting neutralizing monoclonal antibodies and a maternal vaccine for passive immunization of newborns, and three vaccines for adults aged 60\u00a0years and older who are vulnerable to RSV disease, have the potential to prevent severe RSV-associated disease if implemented successfully. The use of these agents will be implemented in some Italian regions over the next few months, although no consistent timelines or decisions for adoption at the national level are expected. A multidisciplinary group of experts in neonatology, obstetrics and gynecology, respiratory medicine, geriatric medicine, hygiene, and public health reviewed the evidence on RSV prevention and present here their considerations on implementing an RSV prevention strategy in Italy. Given the associated disease burden, it is essential to move quickly to deploy these agents in vulnerable populations, enhance surveillance to accurately detect\/predict seasonal trends in RSV activity and measure the impact of prevention strategies. Continuing research combined with widespread use of more sensitive testing is needed to identify vulnerable populations and risk factors. Policies are needed to support these preventive measures in the Italian healthcare system, and access must be accompanied by educational initiatives and advocacy to promote acceptance by HCPs and the target population.<\/jats:p>","DOI":"10.1186\/s41479-025-00160-4","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T01:33:37Z","timestamp":1743816817000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prevention of respiratory syncytial virus disease across the lifespan in Italy"],"prefix":"10.1186","volume":"17","author":[{"given":"Paolo","family":"Manzoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Baraldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Cetin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Ricc\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Siliquini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Sotgiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Viora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,5]]},"reference":[{"key":"160_CR1","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1099\/jgv.0.000959","volume":"98","author":"B Rima","year":"2017","unstructured":"Rima B, Collins P, Easton A, Fouchier R, Kurath G, Lamb RA, et al. ICTV virus taxonomy profile: pneumoviridae. J Gen Virol. 2017;98:2912\u20133.","journal-title":"J Gen Virol"},{"key":"160_CR2","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1056\/NEJMoa0804877","volume":"360","author":"CB Hall","year":"2009","unstructured":"Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360:588\u201398.","journal-title":"N Engl J Med"},{"key":"160_CR3","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1186\/s12879-014-0665-2","volume":"14","author":"C Volling","year":"2014","unstructured":"Volling C, Hassan K, Mazzulli T, Green K, Al-Den A, Hunter P, et al. Respiratory syncytial virus infection-associated hospitalization in adults: a retrospective cohort study. BMC Infect Dis. 2014;14:665.","journal-title":"BMC Infect Dis"},{"key":"160_CR4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s12016-013-8368-9","volume":"45","author":"AT Borchers","year":"2013","unstructured":"Borchers AT, Chang C, Gershwin ME, Gershwin LJ. Respiratory syncytial virus\u2013a comprehensive review. Clin Rev Allergy Immunol. 2013;45:331\u201379.","journal-title":"Clin Rev Allergy Immunol"},{"key":"160_CR5","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.3390\/microorganisms8122048","volume":"8","author":"S Bianchini","year":"2020","unstructured":"Bianchini S, Silvestri E, Argentiero A, Fainardi V, Pisi G, Esposito S. Role of respiratory syncytial virus in pediatric pneumonia. Microorganisms. 2020;8:2048.","journal-title":"Microorganisms"},{"key":"160_CR6","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa043951","volume":"352","author":"AR Falsey","year":"2005","unstructured":"Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352:1749\u201359.","journal-title":"N Engl J Med"},{"key":"160_CR7","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1211917","volume":"368","author":"MO Blanken","year":"2013","unstructured":"Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JLL, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368:1791\u20139.","journal-title":"N Engl J Med"},{"key":"160_CR8","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1002\/ppul.24676","volume":"55","author":"J Coutts","year":"2020","unstructured":"Coutts J, Fullarton J, Morris C, Grubb E, Buchan S, Rodgers-Gray B, et al. Association between respiratory syncytial virus hospitalization in infancy and childhood asthma. Pediatr Pulmonol. 2020;55:1104\u201310.","journal-title":"Pediatr Pulmonol"},{"key":"160_CR9","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1016\/j.vaccine.2020.01.020","volume":"38","author":"AJ Driscoll","year":"2020","unstructured":"Driscoll AJ, Arshad SH, Bont L, Brunwasser SM, Cherian T, Englund JA, et al. Does respiratory syncytial virus lower respiratory illness in early life cause recurrent wheeze of early childhood and asthma? Critical review of the evidence and guidance for future studies from a World Health Organization-sponsored meeting. Vaccine. 2020;38:2435\u201348.","journal-title":"Vaccine"},{"key":"160_CR10","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.jaip.2021.12.005","volume":"10","author":"NB Achten","year":"2022","unstructured":"Achten NB, van Rossum AMC, Bacharier LB, Fitzpatrick AM, Hartert TV. Long-term respiratory consequences of early-life respiratory viral infections: a pragmatic approach to fundamental questions. J Allergy Clin Immunol Pract. 2022;10:664\u201370.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"160_CR11","doi-asserted-by":"publisher","first-page":"e0296685","DOI":"10.1371\/journal.pone.0296685","volume":"19","author":"A Shiroshita","year":"2024","unstructured":"Shiroshita A, Gebretsadik T, Wu P, Kubilay NZ, Hartert TV. Association between age of respiratory syncytial virus infection hospitalization and childhood asthma: a systematic review. PLoS One. 2024;19:e0296685.","journal-title":"PLoS ONE"},{"key":"160_CR12","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1055\/s-0040-1714345","volume":"37","author":"E Baraldi","year":"2020","unstructured":"Baraldi E, Bonadies L, Manzoni P. Evidence on the link between respiratory syncytial virus infection in early life and chronic obstructive lung diseases. Am J Perinatol. 2020;37:S26-30.","journal-title":"Am J Perinatol"},{"key":"160_CR13","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1164\/rccm.200509-1489OC","volume":"173","author":"TMA Wilkinson","year":"2006","unstructured":"Wilkinson TMA, Donaldson GC, Johnston SL, Openshaw PJM, Wedzicha JA. Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173:871\u20136.","journal-title":"Am J Respir Crit Care Med"},{"key":"160_CR14","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1093\/infdis\/jiaa361","volume":"222","author":"HF Tseng","year":"2020","unstructured":"Tseng HF, Sy LS, Ackerson B, Solano Z, Slezak J, Luo Y, et al. Severe morbidity and short- and mid- to long-term mortality in older adults hospitalized with respiratory syncytial virus infection. J Infect Dis. 2020;222:1298\u2013310.","journal-title":"J Infect Dis"},{"key":"160_CR15","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1111\/irv.13043","volume":"16","author":"AR Branche","year":"2022","unstructured":"Branche AR, Saiman L, Walsh EE, Falsey AR, Jia H, Barrett A, et al. Change in functional status associated with respiratory syncytial virus infection in hospitalized older adults. Influenza Other Respir Viruses. 2022;16:1151\u201360.","journal-title":"Influenza Other Respir Viruses"},{"key":"160_CR16","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1164\/rccm.201604-0753OC","volume":"194","author":"CE Berry","year":"2016","unstructured":"Berry CE, Billheimer D, Jenkins IC, Lu ZJ, Stern DA, Gerald LB, et al. A distinct low lung function trajectory from childhood to the fourth decade of life. Am J Respir Crit Care Med. 2016;194:607\u201312.","journal-title":"Am J Respir Crit Care Med"},{"key":"160_CR17","unstructured":"European Medicines Agency. Abrysvo - summary of product characteristics. 2023. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/abrysvo-epar-product-information_en.pdf. Accessed 2 Aug 2024."},{"key":"160_CR18","unstructured":"European Medicines Agency. Synagis - summary of product characteristics. 2009. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/synagis-epar-product-information_en.pdf. Accessed 2 Aug 2024."},{"key":"160_CR19","unstructured":"European Medicines Agency. Beyfortus - summary of product characteristics. 2022. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/beyfortus-epar-product-information_en.pdf. Accessed 2 Aug 2024."},{"key":"160_CR20","unstructured":"European Medicines Agency. Arexvy - summary of product characteristics. 2023. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/arexvy-epar-product-information_en.pdf. Accessed 2 Aug 2024."},{"key":"160_CR21","unstructured":"European Medicines Agency. mResvia - product details. 2024. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mresvia#product-details. Accessed 2 Aug 2024."},{"key":"160_CR22","unstructured":"Associazione italiana di Ostetricia (A\u0399\u039f), Associazione Ostetrici Ginecologi Ospedalieri Italiani (AOGOI), Federazione Nazionale degli Ordini della Professione di Ostetrica (FNOPO), Societ\u00e0 Italiana di Ginecologia e Ostetrica (SIGO), Societ\u00e0 italiana di Medicina Perinatale (SIMP), Societ\u00e0 italiana di Neonatologi (SIN), et al. Vaccinazione contro il virus respiratorio sinciziale in gravidanza. Available from: https:\/\/www.sigo.it\/wp-content\/uploads\/2024\/03\/Position_Paper_VRS.pdf. Accessed 2 Aug 2024."},{"key":"160_CR23","unstructured":"Italian Pediatric Society. Societ\u00e0 Italiana di Pediatria Posizione del Board Calendario per la Vita e SIN su Anticorpo Monoclonale per Prevenzione Malattie da VRS. Available from: https:\/\/sip.it\/2023\/02\/17\/vrs-calendario-per-la-vita-e-sin\/. Accessed 2 Aug 2024."},{"key":"160_CR24","unstructured":"Italian Vaccination Commission. Raccomandazioni del Board del Calendario per la Vita sulla vaccinazione contro Virus Respiratorio Sinciziale (VRS o RSV) nella popolazione anziana e negli adulti a rischio. 2024. Available from: https:\/\/www.igienistionline.it\/docs\/2024\/01pp.pdf. Accessed 2 Aug 2024."},{"key":"160_CR25","unstructured":"Societ\u00e0 Italiana Igiene, Medicina Preventiva e Sanit\u00e0 Pubblica (SItI), Societ\u00e0 Italiana Malattie Infettive e Tropicali (SIMIT). Prevenzione delle infezioni da Virus Respiratorio Sinciziale nella popolazione italiana. Available from: https:\/\/trendsanita.it\/wp-content\/uploads\/2024\/02\/Documento_Prevenzione-infezioni-VRS_SItI-SIMIT.pdf. Accessed 2 Aug 2024."},{"key":"160_CR26","unstructured":"Italian Ministry of Health. Misure di prevenzione e immunizzazione contro il virus respiratorio sinciziale (VRS). CIRCULAR n. 9486. 2024. Available from: https:\/\/www.trovanorme.salute.gov.it\/norme\/renderNormsanPdf?anno=2024&codLeg=99716&parte=1%20&serie=null. Accessed 2 Aug 2024."},{"key":"160_CR27","unstructured":"FIMP - Federazione Italiana Medici Pediatri. Virus Respiratorio Sinciziale: i Pediatri di Famiglia della FIMP pronti a fare la propria parte per attuare una strategia di prevenzione universale per i nuovi nati. 2023. Available from: https:\/\/www.fimp.pro\/comunicati-stampa\/virus-respiratorio-sinciziale-i-pediatri-di-famiglia-della-fimp-pronti-a-fare-la-propria-parte-per-attuare-una-strategia-di-prevenzione-universale-per-i-nuovi-nati. Accessed 2 Aug 2024."},{"key":"160_CR28","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1080\/21645515.2017.1403707","volume":"14","author":"S Janet","year":"2018","unstructured":"Janet S, Broad J, Snape MD. Respiratory syncytial virus seasonality and its implications on prevention strategies. Hum Vaccines Immunother. 2018;14:234\u201344.","journal-title":"Hum Vaccines Immunother"},{"key":"160_CR29","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1093\/infdis\/jiad192","volume":"229","author":"S Deng","year":"2024","unstructured":"Deng S, Guo L, Cohen C, Meijer A, Moyes J, Pasittungkul S, et al. Impact of subgroup distribution on seasonality of human respiratory syncytial virus: a global systematic analysis. J Infect Dis. 2024;229:S25-33.","journal-title":"J Infect Dis"},{"key":"160_CR30","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13052-021-01148-8","volume":"47","author":"C Azzari","year":"2021","unstructured":"Azzari C, Baraldi E, Bonanni P, Bozzola E, Coscia A, Lanari M, et al. Epidemiology and prevention of respiratory syncytial virus infections in children in Italy. Ital J Pediatr. 2021;47:198.","journal-title":"Ital J Pediatr"},{"key":"160_CR31","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1002\/jmv.25917","volume":"92","author":"L Pellegrinelli","year":"2020","unstructured":"Pellegrinelli L, Galli C, Bubba L, Cereda D, Anselmi G, Binda S, et al. Respiratory syncytial virus in influenza-like illness cases: Epidemiology and molecular analyses of four consecutive winter seasons (2014\u20132015\/2017-2018) in Lombardy (Northern Italy). J Med Virol. 2020;92:2999\u20133006.","journal-title":"J Med Virol"},{"key":"160_CR32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/vaccines8010015","volume":"8","author":"F Barbati","year":"2020","unstructured":"Barbati F, Moriondo M, Pisano L, Calistri E, Lodi L, Ricci S, et al. Epidemiology of respiratory syncytial virus-related hospitalization over a 5-year period in Italy: evaluation of seasonality and age distribution before vaccine introduction. Vaccines. 2020;8:15.","journal-title":"Vaccines"},{"key":"160_CR33","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13052-019-0704-0","volume":"45","author":"C Ciarlitto","year":"2019","unstructured":"Ciarlitto C, Vittucci AC, Antilici L, Concato C, Di Camillo C, Zangari P, et al. Respiratory Syncityal Virus A and B: three bronchiolitis seasons in a third level hospital in Italy. Ital J Pediatr. 2019;45:115.","journal-title":"Ital J Pediatr"},{"key":"160_CR34","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1086\/315508","volume":"181","author":"TC Peret","year":"2000","unstructured":"Peret TC, Hall CB, Hammond GW, Piedra PA, Storch GA, Sullender WM, et al. Circulation patterns of group A and B human respiratory syncytial virus genotypes in 5 communities in North America. J Infect Dis. 2000;181:1891\u20136.","journal-title":"J Infect Dis"},{"key":"160_CR35","unstructured":"Italian National Institute of Health. RespiVirNet. Sorveglianza Epidemiologica e Virologica dei casi di sindromi similinfluenzali e dei virus respiratori. Protocollo operativo Stagione 2023\u20132024. 2023. Available from: https:\/\/www.salute.gov.it\/portale\/influenza\/dettaglioPubblicazioniInfluenza.jsp?lingua=italiano&id=3371. Accessed 2 Aug 2024."},{"key":"160_CR36","unstructured":"RespiVirNet-Istituto Superiore di Sanit\u00e0. Rapporto della sorveglianza integrata dei virus respiratori - Stagione 2023\/2024. 2024. Available from: https:\/\/www.epicentro.iss.it\/influenza\/respinews#vir. Accessed 2 Aug 2024."},{"key":"160_CR37","first-page":"491","volume":"9","author":"A Camporesi","year":"2022","unstructured":"Camporesi A, Morello R, Ferro V, Pierantoni L, Rocca A, Lanari M, et al. Epidemiology, microbiology and severity of bronchiolitis in the first post-lockdown cold season in three different geographical areas in Italy: a prospective, observational study. Child Basel Switz. 2022;9:491.","journal-title":"Child Basel Switz"},{"key":"160_CR38","first-page":"848","volume":"9","author":"D Loconsole","year":"2022","unstructured":"Loconsole D, Centrone F, Rizzo C, Caselli D, Orlandi A, Cardinale F, et al. Out-of-season epidemic of respiratory syncytial virus during the COVID-19 pandemic: the high burden of child hospitalization in an academic hospital in Southern Italy in 2021. Child Basel Switz. 2022;9:848.","journal-title":"Child Basel Switz"},{"key":"160_CR39","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.3390\/ijerph20054565","volume":"20","author":"S Cocchio","year":"2023","unstructured":"Cocchio S, Prandi GM, Furlan P, Venturato G, Saia M, Marcon T, et al. Respiratory syncytial virus in Veneto Region: analysis of hospital discharge records from 2007 to 2021. Int J Environ Res Public Health. 2023;20:4565.","journal-title":"Int J Environ Res Public Health"},{"key":"160_CR40","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3390\/v16010126","volume":"16","author":"D Treggiari","year":"2024","unstructured":"Treggiari D, Pomari C, Zavarise G, Piubelli C, Formenti F, Perandin F. Characteristics of respiratory syncytial virus infections in children in the post-COVID seasons: a Northern Italy hospital experience. Viruses. 2024;16:126.","journal-title":"Viruses"},{"key":"160_CR41","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1007\/s10238-022-00973-3","volume":"23","author":"A Pierangeli","year":"2023","unstructured":"Pierangeli A, Piralla A, Uceda Renteria S, Giacomel G, Lunghi G, Pagani E, et al. Multicenter epidemiological investigation and genetic characterization of respiratory syncytial virus and metapneumovirus infections in the pre-pandemic 2018\u20132019 season in northern and central Italy. Clin Exp Med. 2023;23:2725\u201337.","journal-title":"Clin Exp Med"},{"key":"160_CR42","doi-asserted-by":"publisher","first-page":"105681","DOI":"10.1016\/j.jcv.2024.105681","volume":"173","author":"A Pierangeli","year":"2024","unstructured":"Pierangeli A, Midulla F, Piralla A, Ferrari G, Nenna R, Pitrolo AMG, et al. Sequence analysis of respiratory syncytial virus cases reveals a novel subgroup -B strain circulating in north-central Italy after pandemic restrictions. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2024;173:105681.","journal-title":"J Clin Virol Off Publ Pan Am Soc Clin Virol"},{"key":"160_CR43","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1093\/infdis\/jiab452","volume":"226","author":"K Korsten","year":"2022","unstructured":"Korsten K, Adriaenssens N, Coenen S, Butler CC, Verheij TJM, Bont LJ, et al. World Health Organization Influenza-like illness underestimates the burden of respiratory syncytial virus infection in community-dwelling older adults. J Infect Dis. 2022;226:S71-8.","journal-title":"J Infect Dis"},{"key":"160_CR44","doi-asserted-by":"publisher","first-page":"e2112410119","DOI":"10.1073\/pnas.2112410119","volume":"119","author":"JA Lewnard","year":"2022","unstructured":"Lewnard JA, Fries LF, Cho I, Chen J, Laxminarayan R. Prevention of antimicrobial prescribing among infants following maternal vaccination against respiratory syncytial virus. Proc Natl Acad Sci U S A. 2022;119:e2112410119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"160_CR45","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1038\/s41467-024-47118-6","volume":"15","author":"AC Langedijk","year":"2024","unstructured":"Langedijk AC, Vrancken B, Lebbink RJ, Wilkins D, Kelly EJ, Baraldi E, et al. The genomic evolutionary dynamics and global circulation patterns of respiratory syncytial virus. Nat Commun. 2024;15:3083.","journal-title":"Nat Commun"},{"key":"160_CR46","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1093\/infdis\/jiad189","volume":"228","author":"R Osei-Yeboah","year":"2023","unstructured":"Osei-Yeboah R, Spreeuwenberg P, Del Riccio M, Fischer TK, Egeskov-Cavling AM, B\u00f8\u00e5s H, et al. Estimation of the number of respiratory syncytial virus-associated hospitalizations in adults in the European union. J Infect Dis. 2023;228:1539\u201348.","journal-title":"J Infect Dis"},{"key":"160_CR47","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2213-2600(22)00414-3","volume":"11","author":"JG Wildenbeest","year":"2023","unstructured":"Wildenbeest JG, Billard M-N, Zuurbier RP, Korsten K, Langedijk AC, van de Ven PM, et al. The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study. Lancet Respir Med. 2023;11:341\u201353.","journal-title":"Lancet Respir Med"},{"key":"160_CR48","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13052-024-01628-7","volume":"50","author":"M Dovizio","year":"2024","unstructured":"Dovizio M, Veronesi C, Bartolini F, Cavaliere A, Grego S, Pagliaro R, et al. Clinical and economic burden of respiratory syncytial virus in children aged 0\u20135 years in Italy. Ital J Pediatr. 2024;50:57.","journal-title":"Ital J Pediatr"},{"key":"160_CR49","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.3390\/vaccines11091484","volume":"11","author":"S Boccalini","year":"2023","unstructured":"Boccalini S, Bonito B, Salvati C, Del Riccio M, Stancanelli E, Bruschi M, et al. Human respiratory syncytial virus epidemiological burden in pediatric outpatients in Italy: a systematic review. Vaccines. 2023;11:1484.","journal-title":"Vaccines"},{"key":"160_CR50","doi-asserted-by":"publisher","first-page":"1143735","DOI":"10.3389\/fped.2023.1143735","volume":"11","author":"E Barbieri","year":"2023","unstructured":"Barbieri E, Cavagnis S, Scamarcia A, Cantarutti L, Bertizzolo L, Bangert M, et al. Assessing the burden of bronchiolitis and lower respiratory tract infections in children \u226424 months of age in Italy, 2012\u20132019. Front Pediatr. 2023;11:1143735.","journal-title":"Front Pediatr"},{"key":"160_CR51","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1002\/hsr2.91","volume":"1","author":"KN Turi","year":"2018","unstructured":"Turi KN, Wu P, Escobar GJ, Gebretsadik T, Ding T, Walsh EM, et al. Prevalence of infant bronchiolitis-coded healthcare encounters attributable to RSV. Health Sci Rep. 2018;1:e91.","journal-title":"Health Sci Rep"},{"key":"160_CR52","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s40121-023-00758-5","volume":"12","author":"MH Rozenbaum","year":"2023","unstructured":"Rozenbaum MH, Judy J, Tran D, Yacisin K, Kurosky SK, Begier E. Low levels of RSV testing among adults hospitalized for lower respiratory tract infection in the United States. Infect Dis Ther. 2023;12:677\u201385.","journal-title":"Infect Dis Ther"},{"key":"160_CR53","first-page":"106968","volume":"141","author":"A Domnich","year":"2024","unstructured":"Domnich A, Orsi A, Ogliastro M, Ferrari A, Bruzzone B, Panatto D, et al. Influenza-like illness surveillance may underestimate the incidence of respiratory syncytial virus in adult outpatients. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2024;141:106968.","journal-title":"Int J Infect Dis IJID Off Publ Int Soc Infect Dis"},{"key":"160_CR54","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/infdis\/jiad012","volume":"228","author":"C Onwuchekwa","year":"2023","unstructured":"Onwuchekwa C, Moreo LM, Menon S, Machado B, Curcio D, Kalina W, et al. Underascertainment of respiratory syncytial virus infection in adults due to diagnostic testing limitations: a systematic literature review and meta-analysis. J Infect Dis. 2023;228:173\u201384.","journal-title":"J Infect Dis"},{"key":"160_CR55","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s40121-023-00805-1","volume":"12","author":"J Ramirez","year":"2023","unstructured":"Ramirez J, Carrico R, Wilde A, Junkins A, Furmanek S, Chandler T, et al. Diagnosis of respiratory syncytial virus in adults substantially increases when adding sputum, saliva, and serology testing to nasopharyngeal swab RT-PCR. Infect Dis Ther. 2023;12:1593\u2013603.","journal-title":"Infect Dis Ther"},{"key":"160_CR56","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1164\/rccm.202403-0649ED","volume":"210","author":"F Baraldi","year":"2024","unstructured":"Baraldi F, Contoli M, Papi A. The convoluted journey to unveil the Respiratory Syncytial Virus (RSV) in Chronic Obstructive Pulmonary Disease (COPD) exacerbations: old paths and new traces. Am J Respir Crit Care Med. 2024;210:967\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"160_CR57","doi-asserted-by":"publisher","first-page":"S577","DOI":"10.1093\/infdis\/jiz059","volume":"222","author":"T Shi","year":"2020","unstructured":"Shi T, Denouel A, Tietjen AK, Campbell I, Moran E, Li X, et al. Global Disease Burden estimates of respiratory syncytial virus-associated acute respiratory infection in older adults in 2015: a systematic review and meta-analysis. J Infect Dis. 2020;222:S577-83.","journal-title":"J Infect Dis"},{"key":"160_CR58","first-page":"1538","volume":"29","author":"D Bouzid","year":"2023","unstructured":"Bouzid D, Visseaux B, Ferr\u00e9 VM, Peiffer-Smadja N, Le Hingrat Q, Loubet P. Respiratory syncytial virus in adults with comorbidities: an update on epidemiology, vaccines, and treatments. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2023;29:1538\u201350.","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis"},{"key":"160_CR59","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/QCO.0000000000001000","volume":"37","author":"S Kenmoe","year":"2024","unstructured":"Kenmoe S, Nair H. The disease burden of respiratory syncytial virus in older adults. Curr Opin Infect Dis. 2024;37:129\u201336.","journal-title":"Curr Opin Infect Dis"},{"key":"160_CR60","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1093\/infdis\/jiad510","volume":"229","author":"R Osei-Yeboah","year":"2024","unstructured":"Osei-Yeboah R, Johannesen CK, Egeskov-Cavling AM, Chen J, Lehtonen T, Fornes AU, et al. Respiratory syncytial virus-associated hospitalization in adults with comorbidities in 2 European countries: a modeling study. J Infect Dis. 2024;229:S70-7.","journal-title":"J Infect Dis"},{"key":"160_CR61","doi-asserted-by":"publisher","first-page":"e13031","DOI":"10.1111\/irv.13031","volume":"17","author":"M Savic","year":"2023","unstructured":"Savic M, Penders Y, Shi T, Branche A, Pir\u00e7on J-Y. Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: a systematic literature review and meta-analysis. Influenza Other Respir Viruses. 2023;17:e13031.","journal-title":"Influenza Other Respir Viruses"},{"key":"160_CR62","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.3390\/vaccines10122092","volume":"10","author":"S Maggi","year":"2022","unstructured":"Maggi S, Veronese N, Burgio M, Cammarata G, Ciuppa ME, Ciriminna S, et al. Rate of hospitalizations and mortality of respiratory syncytial virus infection compared to influenza in older people: a systematic review and meta-analysis. Vaccines. 2022;10:2092.","journal-title":"Vaccines"},{"key":"160_CR63","doi-asserted-by":"publisher","first-page":"e244954","DOI":"10.1001\/jamanetworkopen.2024.4954","volume":"7","author":"D Surie","year":"2024","unstructured":"Surie D, Yuengling KA, DeCuir J, Zhu Y, Lauring AS, Gaglani M, et al. Severity of respiratory syncytial virus vs COVID-19 and influenza among hospitalized US adults. JAMA Netw Open. 2024;7:e244954.","journal-title":"JAMA Netw Open"},{"key":"160_CR64","doi-asserted-by":"publisher","first-page":"107404","DOI":"10.1016\/j.rmed.2023.107404","volume":"218","author":"P Santus","year":"2023","unstructured":"Santus P, Radovanovic D, Gismondo MR, Rimoldi SG, Lombardi A, Danzo F, et al. Respiratory syncytial virus burden and risk factors for severe disease in patients presenting to the emergency department with flu-like symptoms or acute respiratory failure. Respir Med. 2023;218:107404.","journal-title":"Respir Med"},{"key":"160_CR65","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1001\/jamainternmed.2024.0212","volume":"184","author":"RC Woodruff","year":"2024","unstructured":"Woodruff RC, Melgar M, Pham H, Sperling LS, Loustalot F, Kirley PD, et al. Acute cardiac events in hospitalized older adults with respiratory syncytial virus infection. JAMA Intern Med. 2024;184:602\u201311.","journal-title":"JAMA Intern Med"},{"key":"160_CR66","doi-asserted-by":"publisher","first-page":"l5021","DOI":"10.1136\/bmj.l5021","volume":"366","author":"HH Nam","year":"2019","unstructured":"Nam HH, Ison MG. Respiratory syncytial virus infection in adults. BMJ. 2019;366:l5021.","journal-title":"BMJ"},{"key":"160_CR67","doi-asserted-by":"publisher","first-page":"e0297608","DOI":"10.1371\/journal.pone.0297608","volume":"19","author":"A Domnich","year":"2024","unstructured":"Domnich A, Calabr\u00f2 GE. Epidemiology and burden of respiratory syncytial virus in Italian adults: a systematic review and meta-analysis. PLoS ONE. 2024;19:e0297608.","journal-title":"PLoS ONE"},{"key":"160_CR68","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s12325-020-01230-3","volume":"37","author":"V Wyffels","year":"2020","unstructured":"Wyffels V, Kariburyo F, Gavart S, Fleischhackl R, Yuce H. A Real-world analysis of patient characteristics and predictors of hospitalization among US medicare beneficiaries with respiratory syncytial virus infection. Adv Ther. 2020;37:1203\u201317.","journal-title":"Adv Ther"},{"key":"160_CR69","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1080\/13696998.2023.2213125","volume":"26","author":"M Grace","year":"2023","unstructured":"Grace M, Colosia A, Wolowacz S, Panozzo C, Ghaswalla P. Economic burden of respiratory syncytial virus infection in adults: a systematic literature review. J Med Econ. 2023;26:742\u201359.","journal-title":"J Med Econ"},{"key":"160_CR70","doi-asserted-by":"crossref","unstructured":"Carrico J, Hicks KA, Wilson E, Panozzo CA, Ghaswalla P. The annual economic burden of respiratory syncytial virus in adults in the United States. J Infect Dis. 2024;230(2):e342\u201352.","DOI":"10.1093\/infdis\/jiad559"},{"key":"160_CR71","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jped.2023.05.003","volume":"99","author":"CR Rocha-Filho","year":"2023","unstructured":"Rocha-Filho CR, Ramalho GS, Martins JWL, Lucchetta RC, Pinto ACPN, da Rocha AP, et al. Economic burden of respiratory syncytial and parainfluenza viruses in children of upper-middle-income countries: a systematic review. J Pediatr (Rio J). 2023;99:537\u201345.","journal-title":"J Pediatr (Rio J)"},{"key":"160_CR72","doi-asserted-by":"publisher","first-page":"ofae097","DOI":"10.1093\/ofid\/ofae097","volume":"11","author":"A Averin","year":"2024","unstructured":"Averin A, Atwood M, Sato R, Yacisin K, Begier E, Shea K, et al. Attributable cost of adult respiratory syncytial virus illness beyond the acute phase. Open Forum Infect Dis. 2024;11:ofae097.","journal-title":"Open Forum Infect Dis"},{"key":"160_CR73","doi-asserted-by":"publisher","first-page":"594898","DOI":"10.3389\/fped.2020.594898","volume":"8","author":"E Bozzola","year":"2020","unstructured":"Bozzola E, Ciarlitto C, Guolo S, Brusco C, Cerone G, Antilici L, et al. Respiratory syncytial virus bronchiolitis in infancy: the acute hospitalization cost. Front Pediatr. 2020;8:594898.","journal-title":"Front Pediatr"},{"key":"160_CR74","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1185\/03007990802484234","volume":"24","author":"KL Lanct\u00f4t","year":"2008","unstructured":"Lanct\u00f4t KL, Masoud ST, Paes BA, Tarride J-E, Chiu A, Hui C, et al. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32\u201335 weeks: a Canadian-based analysis. Curr Med Res Opin. 2008;24:3223\u201337.","journal-title":"Curr Med Res Opin"},{"key":"160_CR75","doi-asserted-by":"publisher","first-page":"e046563","DOI":"10.1136\/bmjopen-2020-046563","volume":"11","author":"R Baral","year":"2021","unstructured":"Baral R, Higgins D, Regan K, Pecenka C. Impact and cost-effectiveness of potential interventions against infant respiratory syncytial virus (RSV) in 131 low-income and middle-income countries using a static cohort model. BMJ Open. 2021;11:e046563.","journal-title":"BMJ Open"},{"key":"160_CR76","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12916-023-02854-2","volume":"21","author":"J Moyes","year":"2023","unstructured":"Moyes J, Tempia S, Walaza S, McMorrow ML, Treurnicht F, Wolter N, et al. The economic burden of RSV-associated illness in children aged < 5 years, South Africa 2011\u20132016. BMC Med. 2023;21:146.","journal-title":"BMC Med"},{"key":"160_CR77","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/irv.12929","volume":"16","author":"D Curran","year":"2022","unstructured":"Curran D, Cabrera ES, Bracke B, Raymond K, Foster A, Umanzor C, et al. Impact of respiratory syncytial virus disease on quality of life in adults aged \u226550 years: a qualitative patient experience cross-sectional study. Influenza Other Respir Viruses. 2022;16:462\u201373.","journal-title":"Influenza Other Respir Viruses"},{"key":"160_CR78","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1016\/j.vaccine.2023.03.024","volume":"41","author":"Z Mao","year":"2023","unstructured":"Mao Z, Li X, Dacosta-Urbieta A, Billard M-N, Wildenbeest J, Korsten K, et al. Economic burden and health-related quality-of-life among infants with respiratory syncytial virus infection: a multi-country prospective cohort study in Europe. Vaccine. 2023;41:2707\u201315.","journal-title":"Vaccine"},{"key":"160_CR79","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1093\/infdis\/jiad477","volume":"229","author":"SF Hak","year":"2024","unstructured":"Hak SF, Venekamp RP, Billard M-N, van Houten MA, Pollard AJ, Heikkinen T, et al. Substantial burden of nonmedically attended RSV infection in healthy-term infants: an international prospective birth cohort study. J Infect Dis. 2024;229:S40-50.","journal-title":"J Infect Dis"},{"key":"160_CR80","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13052-022-01392-6","volume":"49","author":"S Manti","year":"2023","unstructured":"Manti S, Staiano A, Orfeo L, Midulla F, Marseglia GL, Ghizzi C, et al. UPDATE - 2022 Italian guidelines on the management of bronchiolitis in infants. Ital J Pediatr. 2023;49:19.","journal-title":"Ital J Pediatr"},{"key":"160_CR81","doi-asserted-by":"publisher","first-page":"105666","DOI":"10.1016\/j.earlhumdev.2022.105666","volume":"174","author":"A Messina","year":"2022","unstructured":"Messina A, Germano C, Avellis V, Tavella E, Dodaro V, Massaro A, et al. New strategies for the prevention of respiratory syncytial virus (RSV). Early Hum Dev. 2022;174:105666.","journal-title":"Early Hum Dev"},{"key":"160_CR82","unstructured":"US Centers for Disease Control. Preventing respiratory viruses. 2024. Available from: https:\/\/www.cdc.gov\/respiratory-viruses\/prevention\/index.html."},{"key":"160_CR83","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1016\/S0378-3782(13)70016-1","volume":"89 Suppl 1","author":"M Lanari","year":"2013","unstructured":"Lanari M, Prinelli F, Adorni F, Di Santo S, Faldella G, Silvestri M, et al. Maternal milk protects infants against bronchiolitis during the first year of life. Results from an Italian cohort of newborns. Early Hum Dev. 2013;89 Suppl 1:S51-57.","journal-title":"Early Hum Dev"},{"key":"160_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/CMR.13.1.1","volume":"13","author":"WM Sullender","year":"2000","unstructured":"Sullender WM. Respiratory syncytial virus genetic and antigenic diversity. Clin Microbiol Rev. 2000;13:1\u201315.","journal-title":"Clin Microbiol Rev"},{"key":"160_CR85","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1097\/INF.0000000000001596","volume":"36","author":"FR Laham","year":"2017","unstructured":"Laham FR, Mansbach JM, Piedra PA, Hasegawa K, Sullivan AF, Espinola JA, et al. Clinical profiles of respiratory syncytial virus subtypes A AND B among children hospitalized with bronchiolitis. Pediatr Infect Dis J. 2017;36:808\u201310.","journal-title":"Pediatr Infect Dis J"},{"key":"160_CR86","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.coviro.2015.03.002","volume":"11","author":"JS McLellan","year":"2015","unstructured":"McLellan JS. Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein. Curr Opin Virol. 2015;11:70\u20135.","journal-title":"Curr Opin Virol"},{"key":"160_CR87","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","volume":"388","author":"EE Walsh","year":"2023","unstructured":"Walsh EE, P\u00e9rez Marc G, Zareba AM, Falsey AR, Jiang Q, Patton M, et al. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med. 2023;388:1465\u201377.","journal-title":"N Engl J Med"},{"key":"160_CR88","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2209604","volume":"388","author":"A Papi","year":"2023","unstructured":"Papi A, Ison MG, Langley JM, Lee D-G, Leroux-Roels I, Martinon-Torres F, et al. Respiratory syncytial virus prefusion F protein vaccine in older adults. N Engl J Med. 2023;388:595\u2013608.","journal-title":"N Engl J Med"},{"key":"160_CR89","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","volume":"388","author":"B Kampmann","year":"2023","unstructured":"Kampmann B, Madhi SA, Munjal I, Sim\u00f5es EAF, Pahud BA, Llapur C, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388:1451\u201364.","journal-title":"N Engl J Med"},{"key":"160_CR90","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","volume":"389","author":"E Wilson","year":"2023","unstructured":"Wilson E, Goswami J, Baqui AH, Doreski PA, Perez-Marc G, Zaman K, et al. Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults. N Engl J Med. 2023;389:2233\u201344.","journal-title":"N Engl J Med"},{"key":"160_CR91","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1913556","volume":"383","author":"MP Griffin","year":"2020","unstructured":"Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020;383:415\u201325.","journal-title":"N Engl J Med"},{"key":"160_CR92","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S2352-4642(22)00321-2","volume":"7","author":"EAF Sim\u00f5es","year":"2023","unstructured":"Sim\u00f5es EAF, Madhi SA, Muller WJ, Atanasova V, Bosheva M, Caba\u00f1as F, et al. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. Lancet Child Adolesc Health. 2023;7:180\u20139.","journal-title":"Lancet Child Adolesc Health"},{"key":"160_CR93","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1056\/NEJMc2112186","volume":"386","author":"J Domachowske","year":"2022","unstructured":"Domachowske J, Madhi SA, Sim\u00f5es EAF, Atanasova V, Caba\u00f1as F, Furuno K, et al. Safety of nirsevimab for RSV in infants with heart or lung disease or prematurity. N Engl J Med. 2022;386:892\u20134.","journal-title":"N Engl J Med"},{"key":"160_CR94","unstructured":"\u00d6sterreich Nationalen Impfgremium erstellt. The Austrian Vaccination Plan 2023\/2024. 2023. Available from: https:\/\/www.sozialministerium.at\/Themen\/Gesundheit\/Impfen\/Impfplan-%C3%96sterreich.html. Accessed 2 Aug 2024."},{"key":"160_CR95","unstructured":"Belgian Superior Health Counsil. Preventive strategies against RSV disease in children - SHC \u2116 9760. 2023. Available from: https:\/\/www.health.belgium.be\/sites\/default\/files\/uploads\/fields\/fpshealth_theme_file\/20231222_shc-9760_advice_rsv_children_vweb.pdf. Accessed 2 Aug 2024."},{"key":"160_CR96","unstructured":"Belgian Superior Health Counsil. Vaccination against RSV (ADULTS) - SHC \u2116 9725. 2023. Available from: https:\/\/www.health.belgium.be\/sites\/default\/files\/uploads\/fields\/fpshealth_theme_file\/20230918_shc-9725_rsv_vaccination_adults_vweb_1.pdf. Accessed 2 Aug 2024."},{"key":"160_CR97","unstructured":"Haute Autorit\u00e9 de sant\u00e9. Recommandation vaccinale contre les infections \u00e0 VRS chez les femmes enceintes. 2024. Available from: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2024-06\/recommandation_vaccinale_contre_les_infections_a_vrs_chez_les_femmes_enceintes_2024-06-12_16-22-54_898.pdf. Accessed 2 Aug 2024."},{"key":"160_CR98","unstructured":"Haute Autorit\u00e9 de sant\u00e9. R\u00e9ponses Rapides\u202f: Nirs\u00e9vimab (Beyfortus \u00ae) dans la pr\u00e9vention des bronchiolites \u00e0 virus respiratoire syncytial (VRS) chez les nouveau-n\u00e9s et les nourrissons. 2023. Available from: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2023-09\/reponse_rapide__nirsevimab_beyfortus.pdf. Accessed 2 Aug 2024."},{"key":"160_CR99","unstructured":"Haute Autorit\u00e9 de sant\u00e9. Strat\u00e9gie vaccinale de pr\u00e9vention des infections par le VRS chez l\u2019adulte \u00e2g\u00e9 de 60 ans et plus. 2024. Available from: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2024-07\/recommandation_strategie_vaccinale_de_prevention_des_infections_par_le_vrs_chez_ladulte_age_de_60_ans_et_plus..pdf. Accessed 2 Aug 2024."},{"key":"160_CR100","unstructured":"The Standing Committee on Vaccination (STIKO). [Resolution on the recommendation of the STIKO for specific prophylaxis of RSV diseases with nirsevimab in newborns and infants in their 1st RSV season]. Robert Koch Institute; 2024. Report No.: 26. Available from: https:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Archiv\/2024\/Ausgaben\/26_24.pdf?__blob=publicationFile. Accessed 2 Aug 2024."},{"key":"160_CR101","unstructured":"National Immunisation Advisory, Committee (NIAC) - Ireland. Recommendations for passive immunisation and vaccination against respiratory syncytial virus in infants, children and older adults. 2023. Available from: https:\/\/www.nitag-resource.org\/sites\/default\/files\/2023-12\/2023.10.12_NIAC_evidence_synthesis_and_recommendations_re._R.pdf. Accessed 2 Aug 2024."},{"key":"160_CR102","unstructured":"Conseil Superieur des Maladies, Infectieuses - Luxembourg. Recommandations du Conseil sup\u00e9rieur des maladies infectieuses concernant les strat\u00e9gies de pr\u00e9vention des infections au virus RSV chez les nourrissons. 2024. Available from: https:\/\/sante.public.lu\/dam-assets\/fr\/espace-professionnel\/recommandations\/conseil-maladies-infectieuses\/Infection-a-virus-respiratoire-syncitial-_RSV_\/csmi-recommandation-prevention-rsv-ac-et-immunisation.pdf. Accessed 2 Aug 2024."},{"key":"160_CR103","unstructured":"Health Council of the Netherlands. Immunisation against RSV in the first year of life. 2024. Available from: https:\/\/www.healthcouncil.nl\/binaries\/healthcouncil\/documenten\/advisory-reports\/2024\/02\/14\/immunisation-against-rsv-in-the-first-year-of-life\/Immunisation-against-RSV-in-the-first-year-of-life-Summary.pdf. Accessed 2 Aug 2024."},{"key":"160_CR104","unstructured":"Norwegian Institute of Public Health. The vaccination handbook for healthcare personnel - Norway. 2024. Available from: https:\/\/www.fhi.no\/va\/vaksinasjonshandboka\/?term=. Accessed 2 Aug 2024."},{"key":"160_CR105","unstructured":"Ministra Zdrowia. Programu Szczepie\u0144 Ochronnych na rok 2023. 2023. Available from: https:\/\/dziennikmz.mz.gov.pl\/DUM_MZ\/2023\/87\/akt.pdf. Accessed 2 Aug 2024."},{"key":"160_CR106","unstructured":"Ministrica za zdravje Republike Slovenije. Program cepljenja in za\u0161\u010dite z zdravili za leto 2024. Ljubljana; 2024. Available from: https:\/\/www.gov.si\/assets\/ministrstva\/MZ\/DOKUMENTI\/DJZ-Preventiva-in-skrb-za-zdravje\/cepljenje\/Predlog-programa-cepljenja.pdf. Accessed 29 Sep 2024."},{"key":"160_CR107","unstructured":"Comisi\u00f3n de Salud P\u00fablica del Consejo; Interterritorial del Sistema Nacional de Salud. Ministerio de Sanidad. Recomendaciones de utilizaci\u00f3n de nirsevimab para la temporada 2024\u20132025 en Espa\u00f1a. 2024. Available from: https:\/\/www.sanidad.gob.es\/areas\/promocionPrevencion\/vacunaciones\/comoTrabajamos\/docs\/Nirsevimab.pdf. Accessed 2 Aug 2024."},{"key":"160_CR108","unstructured":"L\u00e4kemedelsverkets. L\u00e4kemedelsprofylax mot allvarlig RSVinfektion hos barn inf\u00f6r s\u00e4songen 2023\/2024 \u2013 rekommendation fr\u00e5n L\u00e4kemedelsverket. 2023. Available from: https:\/\/www.lakemedelsverket.se\/4a71a6\/globalassets\/dokument\/behandling-och-forskrivning\/behandlingsrekommendationer\/behandlingsrekommendation\/rekommendation-rsv-barn-sasong-2023-2024.pdf. Accessed 2 Aug 2024."},{"key":"160_CR109","unstructured":"Nirsevimab expert working group: P\u00e9diatrie Suisse\/P\u00e4diatrie Schweiz\/Pediatria Svizzera,, Kinder\u00e4rzte Schweiz, Pediatric Infectious disease Group of Switzerland (PIGS), Swiss Society of Neonatology, Swiss Society of Pediatric Pneumology, Swiss Society of Pediatric Cardiology, Swiss Society for Gynecology and Obstetrics \/ gyn\u00e9cologie Suisse, Swiss society of neuropediatrics, Federal Commission for Vaccination Issues (EKIF \/ CFV), Federal Office of Public Health (FOPH). Consensus statement \/ recommendation on the prevention of respiratory syncytial virus (RSV) infections with the monoclonal antibody Nirsevimab (Beyfortus\u00ae). 2024. Available from: https:\/\/pigs.ch\/wp-content\/uploads\/2024\/02\/Consensus-statement-recommendation-on-the-prevention-of-respiratory-syncytial-virus-RSV-infections-with-the-monoclonal-antibody-Nirsevimab-Beyfortus%C2%AE-1.pdf. Accessed 2 Aug 2024."},{"key":"160_CR110","unstructured":"Eidgen\u00f6ssische Kommission f\u00fcr Impffragen. Protokoll der 99. Plenarsitzung. 2024. Available from: https:\/\/www.bag.admin.ch\/dam\/bag\/de\/dokumente\/mt\/i-und-b\/ekif\/protokolle-2024\/protokoll-plenarsitzung-99-ekif.pdf.download.pdf\/Protokoll%20der%2099.%20Plenarsitzung%20vom%2010.04.2024.pdf. Accessed 2 Aug 2024."},{"key":"160_CR111","unstructured":"The Joint Committee on Vaccination and Immunisation (JCVI). Respiratory syncytial virus (RSV) immunisation programme: JCVI advice, 7 June 2023 Updated 11 September 2023. 2023. Available from: https:\/\/www.gov.uk\/government\/publications\/rsv-immunisation-programme-jcvi-advice-7-june-2023\/respiratory-syncytial-virus-rsv-immunisation-programme-jcvi-advice-7-june-2023. Accessed 2 Aug 2024."},{"key":"160_CR112","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1056\/NEJMoa2305478","volume":"390","author":"I Dieussaert","year":"2024","unstructured":"Dieussaert I, Hyung Kim J, Luik S, Seidl C, Pu W, Stegmann J-U, et al. RSV prefusion F protein-based maternal vaccine - preterm birth and other outcomes. N Engl J Med. 2024;390:1009\u201321.","journal-title":"N Engl J Med"},{"key":"160_CR113","unstructured":"US Food and Drug Administration. Abrysvo prescribing information. 2023. Available from: https:\/\/www.fda.gov\/media\/168889\/download. Accessed 2 Aug 2024."},{"key":"160_CR114","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1093\/infdis\/jiad449","volume":"229","author":"S Kenmoe","year":"2024","unstructured":"Kenmoe S, Chu HY, Dawood FS, Milucky J, Kittikraisak W, Matthewson H, et al. Burden of respiratory syncytial virus-associated acute respiratory infections during pregnancy. J Infect Dis. 2024;229:S51-60.","journal-title":"J Infect Dis"},{"key":"160_CR115","doi-asserted-by":"publisher","first-page":"100289","DOI":"10.1016\/j.xagr.2023.100289","volume":"4","author":"KR Cox","year":"2024","unstructured":"Cox KR, Mandelbaum RS, Brueggmann D, Ouzounian JG, Matsuo K. Pregnant patients with respiratory syncytial virus infection: assessment of characteristics and maternal morbidity at delivery. AJOG Glob Rep. 2024;4:100289.","journal-title":"AJOG Glob Rep"},{"key":"160_CR116","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1164\/rccm.202308-1461OC","volume":"209","author":"IV Trinh","year":"2024","unstructured":"Trinh IV, Desai SP, Ley SH, Mo Z, Satou R, Pridjian GC, et al. Prenatal Infection by respiratory viruses is associated with immunoinflammatory responses in the fetus. Am J Respir Crit Care Med. 2024;209:693\u2013702.","journal-title":"Am J Respir Crit Care Med"},{"key":"160_CR117","doi-asserted-by":"publisher","first-page":"e2419268","DOI":"10.1001\/jamanetworkopen.2024.19268","volume":"7","author":"M Son","year":"2024","unstructured":"Son M, Riley LE, Staniczenko AP, Cron J, Yen S, Thomas C, et al. Nonadjuvanted bivalent respiratory syncytial virus vaccination and perinatal outcomes. JAMA Netw Open. 2024;7:e2419268.","journal-title":"JAMA Netw Open"},{"key":"160_CR118","unstructured":"Jones J, Fleming-Dutra K. Maternal\/Pediatric RSV Work Group - Considerations from the National Center for Immunization and Respiratory Diseases - ACIP General Meeting Presentation. 2024. Available from: https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2024-06-26-28\/05-RSV-Mat-Peds-Jones-508.pdf. Accessed 2 Aug 2024."},{"key":"160_CR119","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/cpdd.883","volume":"10","author":"AO Aliprantis","year":"2021","unstructured":"Aliprantis AO, Wolford D, Caro L, Maas BM, Ma H, Montgomery DL, et al. A Phase 1 randomized, double-blind, placebo-controlled trial to assess the safety, tolerability, and pharmacokinetics of a respiratory syncytial virus neutralizing monoclonal antibody MK-1654 in healthy adults. Clin Pharmacol Drug Dev. 2021;10:556\u201366.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"160_CR120","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1111\/cts.13290","volume":"15","author":"Y Orito","year":"2022","unstructured":"Orito Y, Otani N, Matsumoto Y, Fujimoto K, Oshima N, Maas BM, et al. A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK-1654 in healthy Japanese adults. Clin Transl Sci. 2022;15:1753\u201363.","journal-title":"Clin Transl Sci"},{"key":"160_CR121","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/s41591-023-02316-5","volume":"29","author":"D Wilkins","year":"2023","unstructured":"Wilkins D, Yuan Y, Chang Y, Aksyuk AA, N\u00fa\u00f1ez BS, W\u00e4hlby-Hamr\u00e9n U, et al. Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants. Nat Med. 2023;29:1172\u20139.","journal-title":"Nat Med"},{"key":"160_CR122","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1056\/NEJMoa2110275","volume":"386","author":"LL Hammitt","year":"2022","unstructured":"Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386:837\u201346.","journal-title":"N Engl J Med"},{"key":"160_CR123","first-page":"2400046","volume":"29","author":"M L\u00f3pez-Lacort","year":"2024","unstructured":"L\u00f3pez-Lacort M, Mu\u00f1oz-Quiles C, Mira-Iglesias A, L\u00f3pez-Labrador FX, Mengual-Chuli\u00e1 B, Fern\u00e1ndez-Garc\u00eda C, et al. Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 2024;29:2400046.","journal-title":"Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull"},{"key":"160_CR124","doi-asserted-by":"crossref","unstructured":"Ares-G\u00f3mez S, Mallah N, Santiago-P\u00e9rez M-I, Pardo-Seco J, P\u00e9rez-Mart\u00ednez O, Otero-Barr\u00f3s M-T, et al. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study. Lancet Infect Dis. 2024;24(8):817\u201328.","DOI":"10.1016\/S1473-3099(24)00215-9"},{"key":"160_CR125","doi-asserted-by":"publisher","first-page":"209","DOI":"10.15585\/mmwr.mm7309a4","volume":"73","author":"HL Moline","year":"2024","unstructured":"Moline HL, Tannis A, Toepfer AP, Williams JV, Boom JA, Englund JA, et al. Early estimate of nirsevimab effectiveness for prevention of respiratory syncytial virus-associated hospitalization among infants entering their first respiratory syncytial virus season - new vaccine surveillance network, October 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024;73:209\u201314.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"160_CR126","first-page":"2400033","volume":"29","author":"C Ernst","year":"2024","unstructured":"Ernst C, Bejko D, Gaasch L, Hannelas E, Kahn I, Pierron C, et al. Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023\/24 season in Luxembourg. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 2024;29:2400033.","journal-title":"Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull"},{"key":"160_CR127","doi-asserted-by":"crossref","unstructured":"Coma E, Martinez-Marcos M, Hermosilla E, Mendioroz J, Re\u00f1\u00e9 A, Fina F, et al. Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain). Arch Dis Child. 2024;109(9):736\u201341.","DOI":"10.1136\/archdischild-2024-327153"},{"key":"160_CR128","doi-asserted-by":"publisher","first-page":"e13311","DOI":"10.1111\/irv.13311","volume":"18","author":"J Paireau","year":"2024","unstructured":"Paireau J, Durand C, Raimbault S, Cazaubon J, Mortamet G, Viriot D, et al. Nirsevimab effectiveness against cases of respiratory syncytial virus bronchiolitis hospitalised in paediatric intensive care units in France, September 2023-January 2024. Influenza Other Respir Viruses. 2024;18:e13311.","journal-title":"Influenza Other Respir Viruses"},{"key":"160_CR129","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3390\/vaccines12050549","volume":"12","author":"A Consolati","year":"2024","unstructured":"Consolati A, Farinelli M, Serravalle P, Rollandin C, Apprato L, Esposito S, et al. Safety and efficacy of nirsevimab in a universal prevention program of respiratory syncytial virus bronchiolitis in newborns and infants in the first year of life in the Valle d\u2019Aosta Region, Italy, in the 2023\u20132024 epidemic season. Vaccines. 2024;12:549.","journal-title":"Vaccines"},{"key":"160_CR130","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3390\/vaccines12060640","volume":"12","author":"M Ricc\u00f2","year":"2024","unstructured":"Ricc\u00f2 M, Cascio A, Corrado S, Bottazzoli M, Marchesi F, Gili R, et al. Impact of nirsevimab immunization on pediatric hospitalization rates: a systematic review and meta-analysis (2024). Vaccines. 2024;12:640.","journal-title":"Vaccines"},{"key":"160_CR131","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1017\/S0950268816000352","volume":"144","author":"RM Reeves","year":"2016","unstructured":"Reeves RM, Hardelid P, Gilbert R, Ellis J, Zhao H, Donati M, et al. Epidemiology of laboratory-confirmed respiratory syncytial virus infection in young children in England, 2010\u20132014: the importance of birth month. Epidemiol Infect. 2016;144:2049\u201356.","journal-title":"Epidemiol Infect"},{"key":"160_CR132","doi-asserted-by":"publisher","first-page":"e367","DOI":"10.1016\/S2468-2667(17)30103-2","volume":"2","author":"D Cromer","year":"2017","unstructured":"Cromer D, van Hoek AJ, Newall AT, Pollard AJ, Jit M. Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England. Lancet Public Health. 2017;2:e367-74.","journal-title":"Lancet Public Health"},{"key":"160_CR133","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.15585\/mmwr.mm7241e1","volume":"72","author":"KE Fleming-Dutra","year":"2023","unstructured":"Fleming-Dutra KE, Jones JM, Roper LE, Prill MM, Ortega-Sanchez IR, Moulia DL, et al. Use of the pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants: recommendations of the advisory committee on immunization practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72:1115\u201322.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"160_CR134","doi-asserted-by":"publisher","first-page":"e009693","DOI":"10.1136\/bmjgh-2022-009693","volume":"8","author":"GM Mineva","year":"2023","unstructured":"Mineva GM, Purtill H, Dunne CP, Philip RK. Impact of breastfeeding on the incidence and severity of respiratory syncytial virus (RSV)-associated acute lower respiratory infections in infants: a systematic review highlighting the global relevance of primary prevention. BMJ Glob Health. 2023;8:e009693.","journal-title":"BMJ Glob Health"},{"key":"160_CR135","first-page":"59","volume":"219","author":"NI Mazur","year":"2019","unstructured":"Mazur NI, Horsley NM, Englund JA, Nederend M, Magaret A, Kumar A, et al. Breast milk prefusion F immunoglobulin G as a correlate of protection against respiratory syncytial virus acute respiratory illness. J Infect Dis. 2019;219:59\u201367.","journal-title":"J Infect Dis"},{"key":"160_CR136","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.anpedi.2023.09.006","volume":"99","author":"L Francisco","year":"2023","unstructured":"Francisco L, Cruz-Ca\u00f1ete M, P\u00e9rez C, Couceiro JA, Otheo E, Launes C, et al. Nirsevimab for the prevention of respiratory syncytial virus disease in children. Statement of the Spanish Society of Paediatric Infectious Disease (SEIP). An Pediatr. 2023;99:257\u201363.","journal-title":"An Pediatr"},{"key":"160_CR137","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1093\/infdis\/jiab505","volume":"225","author":"JT Peterson","year":"2022","unstructured":"Peterson JT, Zareba AM, Fitz-Patrick D, Essink BJ, Scott DA, Swanson KA, et al. Safety and immunogenicity of a respiratory syncytial virus prefusion F vaccine when coadministered with a tetanus, diphtheria, and acellular pertussis vaccine. J Infect Dis. 2022;225:2077\u201386.","journal-title":"J Infect Dis"},{"key":"160_CR138","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1056\/NEJMra1509044","volume":"376","author":"SB Omer","year":"2017","unstructured":"Omer SB. Maternal immunization. N Engl J Med. 2017;376:1256\u201367.","journal-title":"N Engl J Med"},{"key":"160_CR139","unstructured":"US CDC\u2019s Advisory Committee on Immunization Practices (ACIP). General best practice guidelines for immunization - timing and spacing of immunobiologics. Available from: https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/timing.html. Accessed 2 Aug 2024."},{"key":"160_CR140","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3390\/vaccines12050500","volume":"12","author":"M Ricc\u00f2","year":"2024","unstructured":"Ricc\u00f2 M, Cascio A, Corrado S, Bottazzoli M, Marchesi F, Gili R, et al. Efficacy of respiratory syncytial virus vaccination to prevent lower respiratory tract illness in older adults: a systematic review and meta-analysis of randomized controlled trials. Vaccines. 2024;12:500.","journal-title":"Vaccines"},{"key":"160_CR141","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S0140-6736(24)01738-0","volume":"404","author":"AB Payne","year":"2024","unstructured":"Payne AB, Watts JA, Mitchell PK, Dascomb K, Irving SA, Klein NP, et al. Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October 2023, to March, 2024: a test-negative design analysis. Lancet. 2024;404:1547\u201359.","journal-title":"Lancet"},{"key":"160_CR142","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1056\/NEJMc2311560","volume":"391","author":"EE Walsh","year":"2024","unstructured":"Walsh EE, P\u00e9rez Marc G, Falsey AR, Jiang Q, Eiras D, Patton M, et al. RENOIR trial - RSVpreF vaccine efficacy over two seasons. N Engl J Med. 2024;391:1459\u201360.","journal-title":"N Engl J Med"},{"key":"160_CR143","doi-asserted-by":"crossref","unstructured":"Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, et al. Efficacy and safety of respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons. Clin Infect Dis. 2024;78(6):1732\u201344.","DOI":"10.1093\/cid\/ciae010"},{"key":"160_CR144","unstructured":"GlaxoSmithKline Inc. Arexvy product monograph. 2023. Available from: https:\/\/ca.gsk.com\/media\/6988\/arexvy.pdf. Accessed 2 Aug 2024."},{"key":"160_CR145","doi-asserted-by":"crossref","unstructured":"Hermida N, Ferguson M, Leroux-Roels I, Pagnussat S, Yaplee D, Hua N, et al. Safety and immunogenicity of respiratory syncytial virus pre-fusion maternal vaccine co-administered with diphtheria-tetanus-pertussis vaccine: a phase 2 study. J Infect Dis. 2024;230(2):e353\u201362.","DOI":"10.1093\/infdis\/jiad560"},{"key":"160_CR146","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1093\/infdis\/jiab611","volume":"225","author":"AR Falsey","year":"2022","unstructured":"Falsey AR, Walsh EE, Scott DA, Gurtman A, Zareba A, Jansen KU, et al. Phase 1\/2 randomized study of the immunogenicity, safety, and tolerability of a respiratory syncytial virus prefusion F vaccine in adults with concomitant inactivated influenza vaccine. J Infect Dis. 2022;225:2056\u201366.","journal-title":"J Infect Dis"},{"key":"160_CR147","unstructured":"Goswami J, Cardona JF, Hsu DC, Simorellis AK, Wilson L, Dhar R, et al. Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial. Lancet Infect Dis. 2024;S1473-3099(24):00589-9."},{"key":"160_CR148","doi-asserted-by":"publisher","first-page":"2303796","DOI":"10.1080\/21645515.2024.2303796","volume":"20","author":"EM La","year":"2024","unstructured":"La EM, Bunniran S, Garbinsky D, Reynolds M, Schwab P, Poston S, et al. Respiratory syncytial virus knowledge, attitudes, and perceptions among adults in the United States. Hum Vaccines Immunother. 2024;20:2303796.","journal-title":"Hum Vaccines Immunother"},{"key":"160_CR149","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3390\/pediatric14020021","volume":"14","author":"M Ricc\u00f2","year":"2022","unstructured":"Ricc\u00f2 M, Ferraro P, Peruzzi S, Zaniboni A, Ranzieri S. Respiratory syncytial virus: knowledge, attitudes and beliefs of general practitioners from North-Eastern Italy (2021). Pediatr Rep. 2022;14:147\u201365.","journal-title":"Pediatr Rep"},{"key":"160_CR150","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ypmed.2019.02.011","volume":"121","author":"A Siani","year":"2019","unstructured":"Siani A. Measles outbreaks in Italy: a paradigm of the re-emergence of vaccine-preventable diseases in developed countries. Prev Med. 2019;121:99\u2013104.","journal-title":"Prev Med"},{"key":"160_CR151","unstructured":"World Health Organization. Strategies for addressing vaccine hesitancy - a systematic review. 2014. Available from: https:\/\/cdn.who.int\/media\/docs\/default-source\/immunization\/sage\/2014\/october\/3-sage-wg-strategies-addressing-vaccine-hesitancy-2014.pdf?sfvrsn=b632b81e_4. Accessed 2 Aug 2024."},{"key":"160_CR152","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/17151635231210879","volume":"157","author":"SKD Houle","year":"2024","unstructured":"Houle SKD, Andrew MK. RSV vaccination in older adults: addressing vaccine hesitancy using the 3C model. Can Pharm J CPJ Rev Pharm Can RPC. 2024;157:39\u201344.","journal-title":"Can Pharm J CPJ Rev Pharm Can RPC"},{"key":"160_CR153","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1080\/14760584.2022.2108799","volume":"21","author":"G Lee Mortensen","year":"2022","unstructured":"Lee Mortensen G, Harrod-Lui K. Parental knowledge about respiratory syncytial virus (RSV) and attitudes to infant immunization with monoclonal antibodies. Expert Rev Vaccines. 2022;21:1523\u201331.","journal-title":"Expert Rev Vaccines"},{"key":"160_CR154","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.3390\/vaccines10081369","volume":"10","author":"I Cetin","year":"2022","unstructured":"Cetin I, Mandalari M, Cesari E, Borriello CR, Ercolanoni M, Preziosi G. SARS-CoV-2 vaccine uptake during pregnancy in regione Lombardia, Italy: a population-based study of 122,942 pregnant women. Vaccines. 2022;10:1369.","journal-title":"Vaccines"},{"key":"160_CR155","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/ijgo.14649","volume":"162","author":"LM Vilca","year":"2023","unstructured":"Vilca LM, Sala V, Chiantera A, Colacurci N, Cetin I. Comprehensive assessment of the implementation of maternal immunization programs in Italy: a national survey across maternity care units. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet. 2023;162:116\u201324.","journal-title":"Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet"},{"key":"160_CR156","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3928\/00989134-20240207-02","volume":"50","author":"MA Gerber","year":"2024","unstructured":"Gerber MA, Burke MK, Brodeur MR. Respiratory syncytial virus vaccination in older adults: considerations for use and shared clinical decision-making. J Gerontol Nurs. 2024;50:7\u201312.","journal-title":"J Gerontol Nurs"},{"key":"160_CR157","doi-asserted-by":"publisher","first-page":"2127290","DOI":"10.1080\/21645515.2022.2127290","volume":"18","author":"AL Eiden","year":"2022","unstructured":"Eiden AL, Barratt J, Nyaku MK. Drivers of and barriers to routine adult vaccination: a systematic literature review. Hum Vaccines Immunother. 2022;18:2127290.","journal-title":"Hum Vaccines Immunother"},{"key":"160_CR158","doi-asserted-by":"publisher","first-page":"2195786","DOI":"10.1080\/21645515.2023.2195786","volume":"19","author":"P Bonanni","year":"2023","unstructured":"Bonanni P, Steffen R, Schelling J, Balaisyte-Jazone L, Posiuniene I, Zato\u0144ski M, et al. Vaccine co-administration in adults: an effective way to improve vaccination coverage. Hum Vaccines Immunother. 2023;19:2195786.","journal-title":"Hum Vaccines Immunother"}],"container-title":["Pneumonia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41479-025-00160-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41479-025-00160-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41479-025-00160-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T01:34:22Z","timestamp":1743816862000},"score":1,"resource":{"primary":{"URL":"https:\/\/pneumonia.biomedcentral.com\/articles\/10.1186\/s41479-025-00160-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,5]]},"references-count":158,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["160"],"URL":"https:\/\/doi.org\/10.1186\/s41479-025-00160-4","relation":{},"ISSN":["2200-6133"],"issn-type":[{"value":"2200-6133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,5]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"P.M. PM declares Speaker and\/or Advisory Board member for Pfizer, Sanofi, MSD, Moderna, Enanta. E.B. declares honoraria for lectures and advisory boards from AstraZeneca, Chiesi, and Sanofi; I.C. has been an Advisory board member for Pfizer; S.M. has been an Advisory board member\/ conference speaker \/researcher, and\/or received educational grants from Sanofi, GSK, Pfizer, Moderna, Viatris, and Merck; M.R. has been an Advisory board member for Pfizer; R.S. reports grants from AstraZeneca, Moderna, Pfizer, Novavax, Sequirus, MSD, Sanofi, GSK, and Viatris; G.S. declares personal payments from INSMED, Pfizer, AstraZeneca, Qiagen; E.V. declares no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}